1. AB0034 Pharmacokinetics and Safety of BCD-057, Adalimumab Biosimilar Candidate, Compared To Humira in Healthy Volunteers (Results of Phase I Clinical Study). (15th July 2016) Authors: Eremeeva, A.; Fogt, S.; Chernyaeva, E.; Kushakova, A.; Ostroukhova, T.; Ivanov, R. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 908 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Early ancient sublineages of Mycobacterium tuberculosis Beijing genotype: unexpected clues from phylogenomics of the pathogen and human history. (August 2019) Authors: Mokrousov, I.; Vyazovaya, A.; Pasechnik, O.; Gerasimova, A.; Dymova, M.; Chernyaeva, E.; Tatarintseva, M.; Stasenko, V. Journal: Clinical microbiology and infection Issue: Volume 25:Number 8(2019) Page Start: 1039.e1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0010 Pharmacokinetics, Safety and Tolerance of BCD-085, A Novel IL-17 Inhibitor, Based on The Results of Phase 1 Clinical Study in Healthy Volunteers. (15th July 2016) Authors: Chernyaeva, E.; Eremeeva, A.; Galustyan, A.; Ivanov, R. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0224 Comparison of Efficacy and Safety of Rituximab Biosimilar, BCD-020, and Innovator Rituximab in Patients with Active Rheumatoid Arthritis Refractory To TNFA Inhibitors. (15th July 2016) Authors: Eremeeva, A.; Chernyaeva, E.; Ivanov, R.; Nasonov, E.; Knyazeva, L. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 513 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0028 Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study. (12th June 2018) Authors: Mazurov, V.; Erdes, S.; Kunder, E.; Soroka, N.; Shesternya, P.; Smakotina, S.; Raskina, T.; Krechikova, D.; Dubinina, T.; Eremeeva, A.; Dokukina, E.; Chernyaeva, E.; Ivanov, R. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0040 Safety, tolerability, pharmacokinetics and pharmacodynamics of bcd-089, novel monoclonal anti-il-6 receptor antibody: results from the first-in-human single dose escalation study in healthy volunteers. (12th June 2018) Authors: Khlyabova, P.; Eremeeva, A.; Lutckii, A.; Dokukina, E.; Chernyaeva, E.; Ivanov, R. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 884 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0206 Results of the alterra clinical trial – the efficacy of the alternative dosing regimen for rituximab biosimilar in bdmards naive patients with rheumatoid arthritis. (12th June 2018) Authors: Mazurov, V.; Denisov, L.; Gordeev, I.; Nesmeyanova, O.; Plaksina, T.; Ilivanova, E.; Krechikova, D.; Zonova, E.; Knyazeva, L.; Artemeva, A.; Dokukina, E.; Chernyaeva, E.; Ivanov, R. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0267 Efficacy and safety of bcd-055, proposed infliximab biosimilar, compared to infliximab: 54-week results from asart-2 phase 3 clinical study. (12th June 2018) Authors: Denisov, L.; Shesternya, P.; Plaksina, T.; Kropotina, T.; Soroka, N.; Kunder, E.; Lutskii, A.; Eremeeva, A.; Dokukina, E.; Chernyaeva, E.; Ivanov, R.; Mazurov, V. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0193 Efficacy and safety of bcd-055 (INFLIXIMAB BIOSIMILAR) in rheumatoid arthritis. results of bcd-055–3/lira phase 3 clinical study. (12th June 2018) Authors: Lila, A.; Denisov, L.; Plaksina, T.; Smakotina, S.; Kunder, E.; Soroka, N.; Kastanayan, A.; Nesmeyanova, O.; Antipova, O.; Ilivanova, E.; Eremeeva, A.; Dokukina, E.; Chernyaeva, E.; Ivanov, R. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗